Payment overview · 2025
General Payments
$1,640.22
80 reported records · 18 companies
Healthcare provider profile · identity verified
Adam Leroy, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LAKEWOOD RANCH, FL · NPI 1922021542
Verified facts
What the public records show
CMS Open Payments records show Adam Leroy, M.D. received $1,640.22 in general payments during 2025 across 80 reported records.
AstraZeneca Pharmaceuticals LP accounted for 15.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 218 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 267 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $248.66 | 15.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $201.33 | 12.3% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $150.81 | 9.2% | 13 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $145.40 | 8.9% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $141.25 | 8.6% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $139.77 | 8.5% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $135.56 | 8.3% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $109.27 | 6.7% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $95.09 | 5.8% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $68.17 | 4.2% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $34.86 | 2.1% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $31.52 | 1.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $29.52 | 1.8% | 1 | 2025 |
| Senseonics, Incorporated | Unresolved — no canonical attribution shown | $27.51 | 1.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.34 | 1.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.13 | 1.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.32 | 1.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.71 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,640.22 | 80 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $248.66 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $187.96 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $150.81 | 13 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $145.40 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $143.57 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $135.56 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $135.22 | 12 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $95.09 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $73.78 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $68.17 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $67.47 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $64.11 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $60.38 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $60.06 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $59.73 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $59.73 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.28 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $38.59 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $38.59 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $34.86 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $31.52 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $29.52 | 1 | 2025 |
Source payment records
|
|||||
| Eversense Normalized: eversense |
Device | Senseonics, Incorporated | $27.51 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.66 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 267 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 34 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 135 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 218 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 25 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
84 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
135 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
218 | 68 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
267 | 73 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1078 | 329 |
| Amlodipine Besylate | Amlodipine Besylate | 920 | 290 |
| Atorvastatin Calcium | Atorvastatin Calcium | 735 | 230 |
| Levothyroxine Sodium | Levothyroxine Sodium | 649 | 201 |
| Lisinopril | Lisinopril | 641 | 201 |
| Metoprolol Succinate | Metoprolol Succinate | 502 | 160 |
| Telmisartan | Telmisartan | 494 | 145 |
| Metformin Hcl Er | Metformin Hcl | 413 | 135 |
| Omeprazole | Omeprazole | 378 | 121 |
| Pantoprazole Sodium | Pantoprazole Sodium | 352 | 125 |
| Tamsulosin Hcl | Tamsulosin Hcl | 299 | 103 |
| Simvastatin | Simvastatin | 271 | 77 |
| Eliquis | Apixaban | 267 | 73 |
| Clopidogrel | Clopidogrel Bisulfate | 244 | 78 |
| Losartan Potassium | Losartan Potassium | 227 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 219 | 66 |
| Ozempic | Semaglutide | 218 | 68 |
| Allopurinol | Allopurinol | 190 | 60 |
| Gabapentin | Gabapentin | 186 | 66 |
| Ramipril | Ramipril | 186 | 83 |
| Carvedilol | Carvedilol | 182 | 56 |
| Alprazolam | Alprazolam | 175 | 71 |
| Furosemide | Furosemide | 168 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 58 |
| Trazodone Hcl | Trazodone Hcl | 155 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 141 | 45 |
| Jardiance | Empagliflozin | 135 | 36 |
| Glimepiride | Glimepiride | 132 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 131 | 46 |
| Sertraline Hcl | Sertraline Hcl | 130 | 37 |
| Alendronate Sodium | Alendronate Sodium | 127 | 42 |
| Atenolol | Atenolol | 117 | 37 |
| Doxazosin Mesylate | Doxazosin Mesylate | 110 | 34 |
| Finasteride | Finasteride | 110 | 38 |
| Prednisone | Prednisone | 109 | 67 |
| Tramadol Hcl | Tramadol Hcl | 108 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 100 | 32 |
| Montelukast Sodium | Montelukast Sodium | 98 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 97 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 31 |
| Famotidine | Famotidine | 95 | 38 |
| Meloxicam | Meloxicam | 95 | 37 |
| Spironolactone | Spironolactone | 95 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 94 | 45 |
| Paroxetine Hcl | Paroxetine Hcl | 87 | 20 |
| Ezetimibe | Ezetimibe | 85 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 36 |
| Synthroid | Levothyroxine Sodium | 84 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | 26 |
| Potassium Chloride | Potassium Chloride | 80 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | 24 |
| Pregabalin | Pregabalin | 78 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 77 | 24 |
| Metformin Hcl | Metformin Hcl | 77 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 33 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 64 | 47 |
| Glyxambi | Empagliflozin/Linagliptin | 63 | 17 |
| Celecoxib | Celecoxib | 62 | 28 |
| Chlorthalidone | Chlorthalidone | 62 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 32 |
| Xarelto | Rivaroxaban | 62 | 16 |
| Warfarin Sodium | Warfarin Sodium | 61 | 15 |
| Valsartan | Valsartan | 58 | 19 |
| Bumetanide | Bumetanide | 54 | 20 |
| Tresiba Flextouch U-200 | Insulin Degludec | 54 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 21 |
| Bupropion Xl | Bupropion Hcl | 52 | 17 |
| Irbesartan | Irbesartan | 50 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 14 |
| Clonidine Hcl | Clonidine Hcl | 49 | 18 |
| Clonazepam | Clonazepam | 48 | 15 |
| Propranolol Hcl | Propranolol Hcl | 48 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | 16 |
| Mounjaro | Tirzepatide | 44 | 13 |
| Estradiol | Estradiol | 43 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 22 |
| Enalapril Maleate | Enalapril Maleate | 42 | suppressed |
| Lorazepam | Lorazepam | 42 | 12 |
| Primidone | Primidone | 41 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 26 |
| Colestipol Hcl | Colestipol Hcl | 38 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Torsemide | Torsemide | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | 12 |
| Temazepam | Temazepam | 34 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | 11 |
| Buspirone Hcl | Buspirone Hcl | 32 | 11 |
| Methocarbamol | Methocarbamol | 32 | 18 |
| Donepezil Hcl | Donepezil Hcl | 31 | 13 |
| Glipizide | Glipizide | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 15 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 28 | 11 |
| Ketoconazole | Ketoconazole | 28 | 17 |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | 20 |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 25 | 20 |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | 13 |
| Kerendia | Finerenone | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 23 | 11 |
| Fenofibrate | Fenofibrate | 23 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Jantoven | Warfarin Sodium | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Clonidine | Clonidine | 21 | suppressed |
| Dexamethasone | Dexamethasone | 21 | 19 |
| Ondansetron Odt | Ondansetron | 21 | 21 |
| Azithromycin | Azithromycin | 20 | 20 |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 19 |
| Anastrozole | Anastrozole | 19 | suppressed |
| Diazepam | Diazepam | 19 | 11 |
| Lovastatin | Lovastatin | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | 11 |
| Colchicine | Colchicine | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 14 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Tadalafil | Tadalafil | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,640.22 · 80 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, Eversense, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, KISUNLA, Kerendia, Korlym, LEQVIO, LINZESS, Leqembi, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VRAYLAR, WATCHMAN FLX, XIFAXAN, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error